THRONCAT is a new startup that aims to transform the field of protein analysis and mRNA therapeutics safety.

THRONCAT began with a mission to make protein analysis more accessible and sensitive. Current techniques for measuring changes in protein synthesis and degradation often fall short in sensitivity and simplicity, limiting scientists’ ability to fully understand disease processes. THRONCAT’s breakthrough lies in a new molecule called β-ethynyl serine (βES). By using βES to label proteins, scientists can profile protein synthesis and degradation with unprecedented sensitivity and ease, enabling detailed and versatile insights into cellular processes. The technology was outlined in a publication in Nature Communications in 2023.

The company is initially focused on the growing market of mRNA therapeutics. mRNA therapies could revolutionize medicine, but safety remains a paramount concern. Recent research has shown that immunogenic protein by-products, such as those produced by some COVID-19 vaccines, can induce harmful immune responses. To tackle this issue, THRONCAT offers a unique service to pharmaceutical companies that are developing mRNA therapeutics.

Using their proprietary THRONCAT metabolic protein labelling technology, the company can enrich protein by-products from mRNA-treated cells, allowing highly sensitive detection via mass spectrometry-based proteomics. Coupled with their bioinformatics platform, THRONCAT recommends optimized mRNA sequences to ensure the safety and efficacy of mRNA therapeutics—minimizing side effects and ensuring their reliability.

Subscribe for alerts on new companies featured on Startups.Bio

View all recently featured startups